Holen Sie sich die Stockscreener-App
0.286
10.00%
0.026
Handel nachbörslich:
.28
-0.006
-2.10%
Schlusskurs vom Vortag:
$0.26
Offen:
$0.2956
24-Stunden-Volumen:
150.94K
Relative Volume:
0.92
Marktkapitalisierung:
$2.50M
Einnahmen:
$24,000
Nettoeinkommen (Verlust:
$-78.06M
KGV:
-0.00986
EPS:
-28.9956
Netto-Cashflow:
$-21.81M
1W Leistung:
+5.93%
1M Leistung:
-4.60%
6M Leistung:
-40.09%
1J Leistung:
-95.02%
1-Tages-Spanne:
$0.2634
$0.2956
1-Wochen-Bereich:
$0.26
$0.308
52-Wochen-Spanne:
$0.24
$8.40
Catheter Precision Inc. Stock (VTAK) Company Profile
Firmenname
Catheter Precision Inc.
Sektor
Branche
Telefon
973 691 2000
Adresse
1670 Highway 160 West, Suite 205, Fort Mill
Vergleichen Sie VTAK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VTAK
Catheter Precision Inc.
|
0.286 | 2.50M | 24,000 | -78.06M | -21.81M | -29.00 |
|
ABT
Abbott Laboratories
|
133.24 | 231.09B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.86 | 155.24B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
380.92 | 144.54B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.48 | 108.82B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
73.68 | 44.31B | 5.54B | 4.18B | 623.10M | 7.00 |
Catheter Precision Inc. Stock (VTAK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2019-08-13 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2018-11-02 | Eingeleitet | Maxim Group | Buy |
Catheter Precision Inc. Aktie (VTAK) Neueste Nachrichten
Catheter Precision Finalizes Strategic Cardiac Acquisition - TipRanks
Catheter Precision completes acquisition of Cardionomic heart failure assets - TipRanks
Catheter Precision (VTAK) Subsidiary Acquires Cardionomic's Hear - GuruFocus
Catheter Precision, Inc. Completes Acquisition of Cardionomic Heart Failure Assets - The Manila Times
Medical Breakthrough: Catheter Precision Takes Over Million-Patient Heart Failure Treatment Innovation - Stock Titan
Catheter Precision (VTAK) Reveals Enhanced Clinical Data on VIVO System | VTAK Stock News - GuruFocus
New Clinical Data Presented about VIVO at the 46th Annual Heart Rhythm Association Conference - The Manila Times
Catheter Precision to Attend and Participate in the 46th Heart Rhythm Society - The Manila Times
Catheter Precision Inc [VTAK] Director makes an insider purchase of 3 shares worth 1.0. - knoxdaily.com
Catheter Precision to Attend and Participate in the 46th Heart R - GuruFocus
Catheter Precision to Attend and Participate in the 46th Heart Rhythm Society | VTAK Stock News - GuruFocus
Breakthrough Cardiac Study: Catheter Precision's VIVO System Achieves 94% Accuracy in European Multi-Center Trial - Stock Titan
Catheter Precision to acquire late-stage heart failure treatment assets in development - MSN
Analytical Lens: Exploring Catheter Precision Inc (VTAK)’s Financial Story Through Ratios - DWinneX
Catheter Precision Inc (VTAK) Stock: A Year of Highs and Lows in the Market - investchronicle.com
Can Catheter Precision Inc (VTAK) meet market expectations this quarter? - uspostnews.com
How analysts predict Five9 Inc (FIVN) will perform this quarter? - uspostnews.com
Catheter Precision (VTAK) Acquires Assets for Cardiac Technology Expansion | VTAK Stock News - GuruFocus
Catheter Precision to acquire assets of Cardionomic related to CPNS system - TipRanks
Catheter Precision to Acquire Assets in Development for Late-Stage Treatment for Acute Decompensated Heart Failure - The Manila Times
Catheter Precision To Acquire Assets In Development For Late-Stage Treatment For Acute Decompensated Heart Failure - marketscreener.com
Breakthrough Heart Failure Treatment Tech With 1M Patient Potential Acquired: Early Clinical Success Revealed - Stock Titan
Catheter Precision Reports 'Going Concern' Notice in Recent Annual Report - marketscreener.com
Catheter Precision Makes NYSE American Section 610(b) Public Announcement - The Manila Times
Catheter Precision Makes NYSE American Section 610(b) Public Announcement | VTAK Stock News - GuruFocus
Catheter Precision, Inc. Announces Receipt of Audit Opinion with Going Concern Doubt - Nasdaq
Crude Oil Gains a Dollar Off China-U.S. Optimism, U.S. EIA Data - The Globe and Mail
Tariff-Driven Volatility Impacting Wall Street Trading Desks - The Globe and Mail
Too Quiet? AI Chip Curbs Ignite Selling—Can Bulls Bounce Back? - The Globe and Mail
Slate Grocery REIT Announces Distribution for the Month of April 2025 - The Globe and Mail
Catheter Precision (VTAK) Secures US Patent for Surgical Closure Device | VTAK Stock News - GuruFocus
Catheter Precision, Inc. Receives Notice of First Patent Allowance in the US for LockeT Product Line - GlobeNewswire
Lachine Hospital Foundation Gala raises $406,500 to support the modernization of Lachine Hospital - The Manila Times
Major Patent Win: Catheter Precision's LockeT Device Gets US Protection Amid Global Expansion - Stock Titan
S&P 500 loses 5%, more than half its prior historic gain, after White House clarifies US is tariffing China at 145% - The Globe and Mail
Tesla Stock’s (TSLA) Tariff Surge Turns Into a Skid - The Globe and Mail
VTAK stock touches 52-week low at $0.3 amid market challenges - Investing.com
VTAK stock touches 52-week low at $0.3 amid market challenges By Investing.com - Investing.com South Africa
Catheter Precision Inc. (VTAK) reports earnings - Quartz
Catheter Precision Q4 2024 revenue jumps 55% to USD 149K - Medical Buyer
Catheter Precision, Inc. Announces Fourth Quarter and Full Year 2024 Update and Financial Results - GlobeNewswire
Impulse Dynamics Receives European CE Mark For Expanded Indication For Diastolic Heart Failure - The Manila Times
Catheter Precision Reports 55% Revenue Jump as LockeT Adoption Accelerates - Stock Titan
Catheter Precision to Participate in and Share Data at Upcoming Industry Conferences - The Manila Times
Breakthrough Study: Catheter Precision's LockeT Outperforms Traditional Methods in 97-Patient Trial - Stock Titan
Imperative Care Expands Precision Thrombectomy Portfolio - Diagnostic and Interventional Cardiology
Imperative Care Expands Symphony Precision Thrombectomy Portfolio with Purpose-Built Design for the Treatment of Venous Thrombosis - Business Wire
VTAK stock touches 52-week low at $0.31 amid market challenges - Investing.com Australia
VTAK stock touches 52-week low at $0.31 amid market challenges By Investing.com - Investing.com South Africa
Global 3D Cardiac Mapping System Market To Reach $2.73 Billion By 2029 With A Growth Rate Of 9.6% As Reveal... - WhaTech
3D Cardiac Mapping System Market To Reach $2.73 Billion By 2029 With A Growth Rate Of 9.6% - WhaTech
Finanzdaten der Catheter Precision Inc.-Aktie (VTAK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.11%
0.79%
Kapitalisierung:
|
Volumen (24h):